NCBI Bookshelf. A service of the National Library of Medicine, National Institutes of Health.
This publication is provided for historical reference only and the information may be out of date.
Structured Abstract
Background:
Radical prostatectomy and radiation therapy for prostate cancer have side effects and unclear survival benefits for early stage and low-risk disease. Prostate cancer often has an indolent natural history, making observational management strategies potentially appealing.
Purpose:
To systematically review the role of active surveillance for triggers to begin curative treatment in men with low-risk prostate cancer. Key Questions address changes in prostate cancer characteristics over time, definitions of active surveillance and other observational strategies, factors affecting the offer of, acceptance of, and adherence to active surveillance, the comparative effectiveness of active surveillance with curative treatments, and research gaps.
Data sources:
MEDLINE®, Cochrane Central Register of Controlled Trials, Cochrane Database of Systematic Reviews, and existing systematic reviews, evidence reports, and economic evaluations.
Study selection:
Randomized controlled trials and nonrandomized comparative studies of treatments, multivariable association studies, and studies of temporal trends in prostate cancer natural history. Only published, peer-reviewed, English-language articles were selected based on predetermined eligibility criteria.
Data extraction:
A standardized protocol was used to extract details on design, diagnoses, interventions, predictive factors, outcomes, and study validity.
Data synthesis:
In total, 80 studies provided information on epidemiologic trends; 56 on definitions of active surveillance; 42 on factors affecting the offer of, acceptance of, or adherence to observational management strategies; and 26 on comparative effectiveness. Increased diagnosis of early-stage prostate cancer due to prostate-specific antigen (PSA) testing, led to an increase in prostate cancer incidence from the mid-1980s to the mid-1990s. The prostate cancer-specific mortality rate decreased for all age groups from the early-1990s to 1999. Currently, patients are diagnosed with earlier stage and lower risk prostate cancers compared to the pre-PSA era. Over time, a lower proportion of men received observational management versus active treatment, even among those with low-risk disease. There was no standardized definition of active surveillance. Sixteen cohorts used different monitoring protocols, all with different combinations of periodic digital rectal examination, PSA testing, rebiopsy, and/or imaging findings. Predictors that a patient received no initial active treatment generally included older age, presence of comorbidities, lower Gleason score, lower tumor stage, lower diagnostic PSA, and lower disease progression risk group. No trial provided results comparing men with localized disease on active surveillance with surgery or radiation therapy.
Limitations:
Because of the nonstandardized usages of the terms “active surveillance” and “watchful waiting” and their intended and often mixed (both curative and palliative) treatment objectives, it was difficult to determine which study patients received active monitoring for triggers indicative of curative treatment and which observation for clinical symptoms indicative of palliative treatment.
Conclusions:
More men are being diagnosed with early stage prostate cancer. Whether active monitoring with a curative intent is an appropriate option for these men remains unclear. A standard, universally agreed-upon definition of active surveillance that clearly distinguishes it from watchful waiting and other observational management strategies is needed to help clarify scientific discourse on this topic. Ongoing clinical trials may provide information on the comparative effectiveness of active surveillance compared to immediate active treatment, but will require long term followup.
Contents
- Preface
- Acknowledgments
- Executive Summary
- Introduction
- Methods
- AHRQ Task Order Officer
- External Expert Input
- Key Questions
- Analytic Framework
- Literature Searches
- Study Selection and Eligibility Criteria
- Data Extraction and Summaries
- Quality Assessment
- Data Synthesis and Presentation
- Summary Tables
- Grading the Body of Evidence for Key Question 4
- Peer Review and Public Commentary
- Results
- Key Question 1 How have the patient population and the natural history of prostate cancer diagnosed in the United States changed in the last 30 years?
- Key Question 2 How are active surveillance and other observational management strategies defined?
- Key Question 3 What factors affect the offer of, acceptance of, and adherence to active surveillance?
- Key Question 4 What are the comparative short- and long-term outcomes of active surveillance versus immediate treatment with curative intent for localized prostate cancer?
- Key Question 5 What are the research needs regarding active surveillance (or watchful waiting) in localized prostate cancer?
- Discussion
- References
- Abbreviations and Acronyms
- Appendixes
Prepared for: Agency for Healthcare Research and Quality, U.S. Department of Health and Human Services1, Contract No. 290-2007-10055-I, Task Order No. 10, Prepared by: Tufts Evidence-based Practice Center, Tufts Medical Center, Boston, MA
Suggested citation:
Ip S, Dahabreh IJ, Chung M, Yu WW, Balk EM, Iovin RC, Mathew P, Luongo T, Dvorak T, Lau J. An Evidence Review of Active Surveillance in Men With Localized Prostate Cancer. Evidence Report/Technology Assessment No. 204. (Prepared by Tufts Evidence-based Practice Center under Contract No. HHSA 290-2007-10055-I.) AHRQ Publication No. 12-E003-EF. Rockville, MD: Agency for Healthcare Research and Quality. December 2011. Available at: www.effectivehealthcare.ahrq.gov/reports/final.cfm.
This report is based on research conducted by the Tufts Evidence-based Practice Center (EPC) under contract to the Agency for Healthcare Research and Quality (AHRQ), Rockville, MD (Contract No. HHSA 290-2007-10055-I). The findings and conclusions in this document are those of the author(s), who are responsible for its contents; the findings and conclusions do not necessarily represent the views of AHRQ. Therefore, no statement in this report should be construed as an official position of AHRQ or of the U.S. Department of Health and Human Services.
The information in this report is intended to help health care researchers and funders of research make well-informed decisions in designing and funding research and thereby improve the quality of health care services. This report is not intended to be a substitute for the application of scientific judgment. Anyone who makes decisions concerning the provision of clinical care should consider this report in the same way as any medical research and in conjunction with all other pertinent information, i.e., in the context of available resources and circumstances.
This report may be used, in whole or in part, as the basis for research design or funding opportunity announcements. AHRQ or the U.S. Department of Health and Human Services endorsement of such derivative products or actions may not be stated or implied.
None of the investigators has any affiliations or financial involvement that conflicts with the material presented in this report.
- 1
540 Gaither Road, Rockville, MD 20850; www
.ahrq.gov
- Review Active surveillance in men with localized prostate cancer: a systematic review.[Ann Intern Med. 2012]Review Active surveillance in men with localized prostate cancer: a systematic review.Dahabreh IJ, Chung M, Balk EM, Yu WW, Mathew P, Lau J, Ip S. Ann Intern Med. 2012 Apr 17; 156(8):582-90. Epub 2012 Feb 20.
- Review Prostate-Specific Antigen-Based Screening for Prostate Cancer: A Systematic Evidence Review for the U.S. Preventive Services Task Force[ 2018]Review Prostate-Specific Antigen-Based Screening for Prostate Cancer: A Systematic Evidence Review for the U.S. Preventive Services Task ForceFenton JJ, Weyrich MS, Durbin S, Liu Y, Bang H, Melnikow J. 2018 May
- Review Systematic review: comparative effectiveness and harms of treatments for clinically localized prostate cancer.[Ann Intern Med. 2008]Review Systematic review: comparative effectiveness and harms of treatments for clinically localized prostate cancer.Wilt TJ, MacDonald R, Rutks I, Shamliyan TA, Taylor BC, Kane RL. Ann Intern Med. 2008 Mar 18; 148(6):435-48. Epub 2008 Feb 4.
- The Prostate Cancer Intervention Versus Observation Trial: VA/NCI/AHRQ Cooperative Studies Program #407 (PIVOT): design and baseline results of a randomized controlled trial comparing radical prostatectomy with watchful waiting for men with clinically localized prostate cancer.[J Natl Cancer Inst Monogr. 2012]The Prostate Cancer Intervention Versus Observation Trial: VA/NCI/AHRQ Cooperative Studies Program #407 (PIVOT): design and baseline results of a randomized controlled trial comparing radical prostatectomy with watchful waiting for men with clinically localized prostate cancer.Wilt TJ. J Natl Cancer Inst Monogr. 2012 Dec; 2012(45):184-90.
- Review Systematic Review and Meta-analysis of Factors Determining Change to Radical Treatment in Active Surveillance for Localized Prostate Cancer.[Eur Urol. 2015]Review Systematic Review and Meta-analysis of Factors Determining Change to Radical Treatment in Active Surveillance for Localized Prostate Cancer.Simpkin AJ, Tilling K, Martin RM, Lane JA, Hamdy FC, Holmberg L, Neal DE, Metcalfe C, Donovan JL. Eur Urol. 2015 Jun; 67(6):993-1005. Epub 2015 Jan 21.
- An Evidence Review of Active Surveillance in Men With Localized Prostate CancerAn Evidence Review of Active Surveillance in Men With Localized Prostate Cancer
- Pressure Ulcer Risk Assessment and Prevention: Comparative EffectivenessPressure Ulcer Risk Assessment and Prevention: Comparative Effectiveness
- Pharmacologic and Mechanical Prophylaxis of Venous Thromboembolism Among Special...Pharmacologic and Mechanical Prophylaxis of Venous Thromboembolism Among Special Populations
- Evaluation and Treatment of CryptorchidismEvaluation and Treatment of Cryptorchidism
- Results - Management of Postpartum HemorrhageResults - Management of Postpartum Hemorrhage
Your browsing activity is empty.
Activity recording is turned off.
See more...